Wblca Benchmark Explorer

https://www.sciencedirect.com › science › article › pii
Atypical hemolytic uremic syndrome aHUS is a rare complex multisystem disease of dysregulated complement

https://clinicaltrials.gov › study
The purpose of the study is to assess the safety and efficacy of ravulizumab to control disease activity in adolescent

https://www.sciencedirect.com › science › article › pii
Ravulizumab is a long acting C5 inhibitor engineered from eculizumab with increased elimination half life allowing an

https://www.kidneymedicinejournal.org › article › fulltext
Atypical hemolytic uremic syndrome aHUS is a rare form of thrombotic microangiopathy TMA caused by

https://www.alexionclinicaltrialtransparency.com › trials
The purpose of the study is to assess the safety and efficacy of ravulizumab to control disease activity in adolescent and adult

https://unifyrare.com › en › hcp › ahus › ultomiris › efficacy
ULTOMIRIS achieved complete TMA response in adult patients with aHUS including patients with a genetic predisposition to

https://link.springer.com › article
Background Atypical hemolytic uremic syndrome aHUS is a rare disease with poor outcomes when untreated in

https://link.springer.com › content › pdf
Conclusions Treatment with ravulizumab provided immediate and complete C5 inhibition resulting in rapid clinical and laboratory

https://www.ncbi.nlm.nih.gov › books › table
Table 43Complete TMA Response and Components Analysis Study 311 PP CI confidence interval LDH lactate